Literature DB >> 18559575

Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program.

Patricia S Steeg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18559575      PMCID： PMC2692037          DOI： 10.1158/1078-0432.CCR-08-1135

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  20 in total

1.  Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes.

Authors:  E Dikicioglu; S Barutca; N Meydan; I Meteoglu
Journal:  Int J Clin Pract       Date:  2005-09       Impact factor: 2.503

2.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

3.  Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.

Authors:  Britta Weigelt; Zhiyuan Hu; Xiaping He; Chad Livasy; Lisa A Carey; Matthew G Ewend; Annuska M Glas; Charles M Perou; Laura J Van't Veer
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

4.  Gene expression profiles of primary breast tumors maintained in distant metastases.

Authors:  Britta Weigelt; Annuska M Glas; Lodewyk F A Wessels; Anke T Witteveen; Johannes L Peterse; Laura J van't Veer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-09       Impact factor: 11.205

5.  Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer.

Authors:  T van Agthoven; M Timmermans; L C Dorssers; S C Henzen-Logmans
Journal:  Int J Cancer       Date:  1995-12-11       Impact factor: 7.396

6.  Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications.

Authors:  Mika Suzuki; David Tarin
Journal:  Mol Oncol       Date:  2007-04-07       Impact factor: 6.603

7.  Expression of ERalpha, ERbeta and Ki-67 in primary tumors and lymph node metastases in breast cancer.

Authors:  Mariusz Koda; Stanislaw Sulkowski; Luiza Kanczuga-Koda; Eva Surmacz; Mariola Sulkowska
Journal:  Oncol Rep       Date:  2004-04       Impact factor: 3.906

8.  Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis.

Authors:  Xishan Hao; Baocun Sun; Limei Hu; Harri Lähdesmäki; Valerie Dunmire; Yumei Feng; Shi-Wu Zhang; Huamin Wang; Chunlei Wu; Hua Wang; Gregory N Fuller; W Fraser Symmans; Ilya Shmulevich; Wei Zhang
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

9.  In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells.

Authors:  L Ding; M Sunamura; T Kodama; J Yamauchi; D G Duda; H Shimamura; K Shibuya; K Takeda; S Matsuno
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

10.  No common denominator for breast cancer lymph node metastasis.

Authors:  B Weigelt; L F A Wessels; A J Bosma; A M Glas; D S A Nuyten; Y D He; H Dai; J L Peterse; L J van't Veer
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640
View more
  15 in total

Review 1.  On the origin of cancer metastasis.

Authors:  Thomas N Seyfried; Leanne C Huysentruyt
Journal:  Crit Rev Oncog       Date:  2013

2.  Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

Authors:  Scott M Knowles; Anna M Wu
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

3.  The NDPK/NME superfamily: state of the art.

Authors:  Mathieu Boissan; Uwe Schlattner; Marie-Lise Lacombe
Journal:  Lab Invest       Date:  2018-02       Impact factor: 5.662

4.  Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients.

Authors:  B Szekely; Zs I Nagy; Zs Farago; O Kiss; G Lotz; K A Kovacs; L Madaras; N Udvarhelyi; M Dank; Gy Szentmartoni; Zs Baranyai; L Harsanyi; A M Tőkés; Jozsef Timar; A M Szasz; J Kulka
Journal:  Clin Exp Metastasis       Date:  2016-11-24       Impact factor: 5.150

5.  Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis.

Authors:  Karin Staflin; Joseph S Krueger; Janna Hachmann; Jane S Forsyth; Mihaela Lorger; Sebastian C J Steiniger; Jenny Mee; Cristina Pop; Guy S Salvesen; Kim D Janda; Brunhilde Felding-Habermann
Journal:  Clin Exp Metastasis       Date:  2010-03-12       Impact factor: 5.150

6.  Cancer as a metabolic disease.

Authors:  Thomas N Seyfried; Laura M Shelton
Journal:  Nutr Metab (Lond)       Date:  2010-01-27       Impact factor: 4.169

Review 7.  Perspectives on the mesenchymal origin of metastatic cancer.

Authors:  Leanne C Huysentruyt; Thomas N Seyfried
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

Review 8.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

Review 9.  Tumor cell dissemination: emerging biological insights from animal models and cancer patients.

Authors:  Yibin Kang; Klaus Pantel
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

Review 10.  Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment.

Authors:  John H Phan; Richard A Moffitt; Todd H Stokes; Jian Liu; Andrew N Young; Shuming Nie; May D Wang
Journal:  Trends Biotechnol       Date:  2009-05-04       Impact factor: 19.536
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.